Approximately 30–50% of NSCLC patients are PD-L1 low, and half of those patients are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative6,7. This evidence concerns the gene EGFR and non-small cell lung carcinoma.